糖尿病醫療設備和藥品市場：按類別、疾病和地區分類

Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，糖尿病相關器材和藥品市場規模將達2,112.1億美元，到2033年將達到4,168.5億美元。預計從2026年到2033年，該市場將以10.2%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	2112.1億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.20%	2033年市場規模預測：	4168.5億美元

糖尿病醫療設備和藥物是指專門用於支援糖尿病管理和治療的器械和藥物。糖尿病是一種以高血糖為特徵的慢性代謝性疾病。這些器械和藥物在監測血糖值、注射胰島素以及控制糖尿病相關症狀和併發症發揮著至關重要的作用。支援糖尿病管理的器材包括血糖值儀、持續血糖監測系統、胰島素幫浦和胰島素筆。藥物則包括胰島素、二甲雙胍、磺醯尿素類藥物和Amylin類似物。這些器械和藥物對於糖尿病患者監測血糖值、注射胰島素以及有效控制病情至關重要，從而降低併發症風險並有助於改善整體健康。

市場動態

全球糖尿病盛行率持續上升，主要原因包括久坐不動的生活方式、不健康的飲食習慣以及肥胖率不斷攀升。糖尿病病例的激增導致對用於監測和治療該疾病的有效醫療設備和藥物的需求顯著成長。在醫療設備領域，持續血糖監測系統（CGM）正日益普及。例如，2022年3月，全球領先的糖尿病患者即時持續血糖監測設備製造商德康醫療（DexCom, Inc.）宣布，其Dexcom G7持續血糖監測（CGM）系統已獲得歐洲CE認證（Conformité European），適用於歐洲2歲及以上糖尿病患者，包括孕婦。

糖尿病藥物市場正取得顯著進展。傳統的治療方法，例如口服降血糖藥物和胰島素注射，仍然佔據市場主導地位。然而，包括腸促胰素、鈉-葡萄糖共同輸送體2 (SGLT-2) 抑制劑和Glucagon-Like Peptide-1(GLP-1) 受體促效劑在內的新型藥物的研發正變得日益重要。這些創新藥物具有更高的療效、更少的副作用和更大的用藥便利性。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球糖尿病治療醫療設備和藥品市場的主要參與者進行了分析：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、型號升級、市場擴張和行銷策略做出明智的決策。
這份全球糖尿病醫療設備和藥品市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球糖尿病醫療設備和藥品市場中使用的各種策略矩陣來簡化決策過程。

概述
北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

公司簡介
雅培實驗室
百時美施貴寶
DexCom, Inc.
禮來公司
伴侶醫療
GlaxoSmithKline Plc
格蘭馬克製藥
強生公司
魯賓公司
F. Hoffmann-La Roche 有限公司
DreaMed Diabetes
Hua Medicine
賽諾菲

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI3857

Diabetes Devices And Drugs Market is estimated to be valued at USD 211.21 Bn in 2026 and is expected to reach USD 416.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 211.21 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.20%	2033 Value Projection:	USD 416.85 Bn

Diabetes devices and drugs refer to the tools and medications specifically designed to help individuals manage and treat diabetes, a chronic metabolic disorder characterized by high blood sugar levels. These devices and drugs play a crucial role in monitoring blood glucose levels, delivering insulin, and controlling the symptoms and complications associated with diabetes. Glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, etc. are a few examples of devices that aid the management of diabetes. Whereas, drugs include insulin, metformin, sulfonylureas, amylin analogues, etc. These devices and drugs are essential for individuals with diabetes to monitor their blood sugar levels, administer insulin, and manage the condition effectively, thereby reducing the risk of complications and promoting overall well-being.

Market Dynamics

The global prevalence of diabetes has been rising steadily primarily driven by the factors such as sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates. This surge in the diabetic population has created a substantial demand for effective devices and drugs to monitor and treat the condition. In terms of devices, continuous glucose monitoring systems have gained significant popularity. For instance, in March 2022, DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System received CE Mark (Conformite Europeenne) for people with diabetes in Europe aged 2 and above, including pregnant women.

The market for diabetes drugs has also witnessed remarkable advancements. Traditional treatments, such as oral antidiabetic drugs and insulin injections, continue to dominate the market. However, there has been a growing emphasis on the development of novel drugs, including incretin-based therapies, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, and (Glucagon-like Peptide-1) GLP-1 receptor agonists. These innovative medications offer improved efficacy and reduced side effects, and enhanced convenience for patients.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global diabetes devices and drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global diabetes devices and drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetes devices and drugs market

Market Segmentation

Global Diabetes Devices and Drugs Market, By Category (Revenue, USD Bn, 2021 - 2033)
Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Other Testing Devices
Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
Global Diabetes Devices and Drugs Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Type 2 Diabetes
Type 1 Diabetes
Global Diabetes Devices and Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Abbott Laboratories
Bristol-Myers Squibb
DexCom
Eli Lilly and Company
Companion Medical
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin Ltd.
Hoffmann-La Roche AG
DreaMed Diabetes
Hua Medicine
Sanofi

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Category
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Pipeline Analysis

4. Global Diabetes Devices and Drugs Market, By Category, 2021 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Diagnosis and Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
  - Blood Glucose Monitoring Devices
  - Software Programs for Diabetes Monitoring
  - Artificial Pancreas
  - Other Testing Devices
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
  - Insulin
  - Insulin Delivery
  - Oral Hypoglycemic Agents
  - Cell Therapies

5. Global Diabetes Devices and Drugs Market, By Disease Type, 2021 - 2033 (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

6. Global Diabetes Devices and Drugs Market, By Region, 2021 - 2033, (US$ Billion)

Overview
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DexCom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Companion Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DreaMed Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hua Medicine
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies